Related Experiment Video

Updated: Mar 27, 2026

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.3K

Axitinib for the treatment of metastatic renal cell carcinoma

Hiral Parekh1, Julianne Griswold1, Brian Rini1

  • 1Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Avenue, Mail Code R35, Cleveland, OH 44195, USA.

Future Oncology (London, England)
|January 16, 2016
PubMed

Insights

Axitinib, a VEGF receptor inhibitor, shows promise for advanced renal cell carcinoma. Research explores its front-line use and optimal dosing, with hypertension linked to better outcomes.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Renal cell carcinoma (RCC) involves VHL gene inactivation, increasing VEGF.
  • VEGF receptor inhibitors are standard for advanced RCC.
  • Axitinib demonstrates superior efficacy over sorafenib in second-line therapy.

Purpose of the Study:

  • To review the development and clinical applications of axitinib.
  • To discuss axitinib's role in metastatic renal cell carcinoma (mRCC).
  • To highlight ongoing research into front-line therapy and dose titration.

Main Methods:

  • Review of clinical trial data and scientific literature.
  • Analysis of axitinib's efficacy and safety profile.
  • Discussion of pharmacologic mechanisms and clinical outcomes.

Main Results:

  • Axitinib is a superior second-line treatment for advanced RCC.
  • Axitinib shows clinical activity in treatment-naive mRCC patients.
  • Hypertension, an axitinib side effect, correlates with improved outcomes.

Conclusions:

  • Axitinib is an important targeted therapy for metastatic renal cell carcinoma.
  • Further investigation is needed for axitinib's front-line use and dose optimization.
  • The association between hypertension and efficacy warrants further study.
Keywords:
VEGF receptor inhibitoraxitinibrenal cell carcinoma

More Related Videos

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

14.4K
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
740
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
472